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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to current chemotherapy regimens, in part due to alterations in
the p53 tumor suppressor pathway. p53 homolog p63 is a transcription factor essential for the development and
differentiation of epithelial surfaces. However its function in cancer is controversial and its role in PDAC is not known. We
discovered that DNp63a was the predominantly expressed p63 variant in pancreatic cancer cell lines. DNp63a protein and
mRNA levels were high in T3M4, BxPC3 and COLO-357 pancreatic cancer cells and low in ASPC-1 and PANC-1 cells.
Overexpression of DNp63a in PANC-1 cells and shRNA-mediated knockdown in T3M4 cells indicated that DNp63a promoted
anchorage-dependent and -independent growth, motility and invasion, and enhanced resistance to cisplatin-induced
apoptosis. Epidermal growth factor receptor (EGFR) signaling pathways contribute to the biological aggressiveness of PDAC,
and we found that the motogenic effects of DNp63a were augmented in presence of EGF. Ectopic expression of DNp63a
resulted in upregulation of EGFR and b1-integrin in PANC-1 cells. Conversely, DNp63a knockdown had an opposite effect in
T3M4 cells. DNp63a potentiated EGF-mediated activation of ERK, Akt and JNK signaling. Chromatin immunoprecipitation
and functional reporter assays demonstrated that DNp63a activated EGFR transcription. 14-3-3s transcription was also
positively regulated by DNp63a and we have previously shown that 14-3-3s contributes to chemoresistance in pancreatic
cancer cell lines. Conversely, shRNA-mediated knockdown of 14-3-3s led to abrogation of the DNp63a effects on cell
proliferation and invasion. Thus, p53 homolog DNp63a enhances the oncogenic potential of pancreatic cancer cells through
trans-activation of EGFR and 14-3-3s.
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Introduction
Studies in human disease demonstrate that most established
tumors carry more than one genetic defect. Pancreatic ductal
adenocarcinoma (PDAC) results from the successive accumulation
of gene mutations [1]. Activating mutations in K-Ras oncogene
and inactivation of tumor suppressors CDKN2A, p53 and SMAD4
are implicated in PDAC development and progression [2]. Gene-
tically engineered mouse models have supported the ‘‘double-hit’’
hypothesiswhereintroductionofeithermutantp53alleleorbiallelic
deletion of ink4a/Arf in mice results in progression of pancreatic
intraepithelial neoplastic lesions with local invasion and metastases
[3,4]. p53 mutations are found in 60 to 70% of PDAC. By contrast,
p63, anancestralmemberofp53family,is rarely mutated incancer.
Six variants of p63 are generated through transcription from two
distinct promoters and alternative splicing. Isoforms transcribed
from P1 contain a full-length trans-activation domain (TAp63a,
b and c). Transcription from P2 generates amino-terminally
truncated variants (DNp63a, b and c), whose exact role in
cancer is not clear. The DNp63 variant is overexpressed in a
variety of human cancers, including tumors of squamous cell
origin (head and neck, lung), breast and bladder [5]. In head and
neck squamous cell carcinoma and ‘‘triple-negative’’ breast
cancer cells, DNp63 suppresses p73-dependent apoptosis and
thus promotes tumor survival [6,7]. By contrast, downregulation
of DNp63a in urothelial carcinoma cell lines promotes cancer
invasiveness [8], suggesting that the DN variant may function in a
cell type-specific manner.
The role of p63 in PDAC is poorly understood. Here we
demonstrate that the DNp63a variant is expressed at variable
levels in PDAC cell lines, and provide evidence that DNp63a
promotes pancreatic cancer cell growth, migration, invasion and
chemoresistance. Via direct transcriptional activation, DNp63a
leads to the up-regulation of epidermal growth factor receptor
(EGFR) and 14-3-3s, sensitizing cancer cells to EGF and
enhancing their oncogenic potential.
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Cell lines
HumanpancreaticcancercelllinesASPC-1,BxPC3andPANC-1;
HEK293 human embryonic kidney cells and H1299 human lung
carcinoma cells were purchased from American Type Culture
Collection (Manassas, VA). COLO-357 and T3M4 human pancre-
atic cancer cell lines were a gift from Dr.R.Metzgar (Duke University,
Durham, NC). Cell lines were grown in RPMI or DMEM (HEK293)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin (complete medium).
Plasmid constructs
The human and mouse DNp63a expression plasmids and
(p53RE)5-tk-luciferase plasmid were reported previously [9].
TAp63a expression plasmid was purchased from Open Biosystems
(Huntsville, AL). pBV-14-3-3s promoter BDS 2 36(p53 binding
site)-luc plasmid was obtained from Addgene (Cambridge, MA).
pGL3-EGFR promoter (p53 binding sites)-luc plasmid was a gift
from Dr. L. Pirisi [10]. Sequence modifications within a coding
of a DNA-binding domain of the human DNp63a expression
plasmid and within EGFR promoter p53 binding site 1 were
introduced using the Quick-Change Site Directed Mutagenesis Kit
(Stratagene, La Jolla, CA).
Immunoblotting
Cells were lysed in RIPA buffer (20 mM Tris, 150 mM NaCl,
1% NP-40, 1 mM NaF, 1 mM Sodium phosphate, 1 mM
NaVO3, 1 nM EDTA, 1 nM EGTA, supplemented with protease
inhibitor cocktail (Roche, Indianapolis, IN) and 1 mM PMSF).
Proteins were analyzed by immunoblotting as previously described
[11]. The following antibodies were used: p63 (4A4; Millipore,
Billerica, MA; 1:500); TAp63c (Li et al., 2006; 1:1,000), 14-3-3s
(Abcam, Cambridge, MA; 1:500), ERK-2 (C-14; Santa Cruz
Biotechnology, Santa Cruz, CA; 1:10,000), p53 (DO-1; Santa
Cruz Biotechnology; 0.4 mg/mL), EGFR (Calbiochem; 1:2,000),
cleaved poly(ADP-ribose) polymerase (PARP), cleaved caspase-3,
ERK-1/2, phospho-ERK1/2 [T202/Y204], Akt, phospho-Akt
[S473] (Cell Signaling Technology, Danvers, MA; 1:1,000), active
JNK (Promega, Madison, WI), horseradish peroxidase-conjugated
anti-mouse and anti-rabbit antibodies (BioRad; 1:5,000).
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated using RNeasy Mini Kit (Qiagen,
Valencia, CA). cDNA was synthesized from 1 mg RNA by random
hexamer priming using the Superscript III RT Kit (Invitrogen,
Carlsbad, CA). Semi-quantitative RT-PCR was carried out using
forward and reverse primers specific for p63 isoforms as previously
published [12]. The following PCR cycling conditions were used:
94uC for 3 min, 35 cycles of 94uC for 40 sec, 55uC for 40 sec, and
72uC for 1.5 min; and 72uC for 4 min.
For the analysis of DNp63 and TAp63 transcript expression
quantitative real time PCR (Q-PCR) was performed in a 7300
Sequence Detector using Universal PCR Master Mix according to
manufacturer’s instructions (Applied Biosystems, Foster City, CA),
template cDNA and gene specific probes (Hs00978339_m1
[DNp63]; Hs00978349_m1 [TAp63]; Applied Biosystems). All
samples were analyzed in duplicates.
Transient transfections, adenoviral infection and
luciferase assays
PANC-1 and T3M4 cells were transiently transfected with
ExGen 500 in vitro Transfection Reagent (Fermentas Life Sciences,
Glen Burnie, MD), using equal amounts of experimental or
control plasmid. Cells were incubated for 48 hours and protein
expression was verified by immunoblotting. The control and
DNp63a-expressing adenovirus were used as described [13].
ASPC-1 and PANC-1 cells were infected with adenovirus at
MOI of ,5 in complete medium for 24 hours.
For luciferase assays, PANC-1 cells were co-transfected with
experimental plasmid or control and the luciferase reporter
construct (pBV-14-3-3s promoter BDS 2 36 (p53 binding site)-
luc; or pGL3-EGFR promoter-luc) along with pCMVb vector
(Clontech Laboratories, Mountain View, CA). The amount of
DNA per transfection was kept constant by using empty
pcDNA3.1 vector. Cells were harvested 48 hours post-transfection
and luciferase assays were performed using the Dual-Luciferase
Reporter Assay System (Promega). Relative light units were
determined using a luminometer (LMaxII
384, Molecular Devices,
Sunnyvale, CA) for firefly luciferase. b-galactosidase activity was
determined using a colorimetric method to normalize transfection
efficiency [14].
Lentiviral shRNA mediated gene silencing
Lentivirus containing shRNA targeting a-specific, TAp63
specific, all p63 isoforms and sh control were described previously
[15]. Lentivirus-based 14-3-3s-targeting and control shRNA were
also described by us previously [11]. Lentiviral particles were
produced by four plasmid transfection system [11]. Knockdown of
p63 isoforms and 14-3-3s in T3M4 and PANC-1 cells was
confirmed by Western blotting and Q-PCR.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
Cells were plated in 96-well plates (3000 cell per well, 6 wells per
sample) and cultured in the absence or presence of 10 mg/mL
cisplatin (Sigma-Aldrich, St. Louis, MO) for 48 hours. MTT
(Sigma-Aldrich) was added at a final concentration 0.55 mg/mL.
After additional 4 hours incubation, absorbance at 570 nm was
determined using an Emax precision microplate reader (Molecular
Devices). We have previously observed that in pancreatic cancer
cell lines the MTT assay correlates with cell growth as determined
in a doubling and [
3H]thymidine incorporation assays [16].
Soft agar assays
Soft agar assays were set up in twelve-well plates, each well
containing a bottom layer of 0.5% Difco agar noble (BD
Biosciences), a middle layer of 0.3% agar including 1500 cells,
and a top layer of 0.3% agar. The plates were incubated for 14
days. Next, 150 mL of 5 mg/mL MTT solution were added to
each well. After incubation at 37uC for 4 hours plates were
photographed and colonies were counted.
Cell migration and invasion assays
Cell motility was assessed in in vitro wound healing and
Transwell migration assays. For wound healing assays, cells were
grown to confluency in 6-well tissue culture plates, and serum-
starved for 12 hours. The resulting cell monolayer was scratched
with a 10 mL pipette tip generating two parallel wounds and
incubated for 18 hours in serum-free medium (SF; 0.1% bovine
serum albumin) in the absence or presence 1 nM EGF (Millipore).
Photographs were taken of each well at four marked locations
under 406 magnification at zero and 18 hours after wounding.
The wound area of matched pictures was measured using the
ImageJ software (National Institutes of Health). For Transwell
migration assays, cell were suspended in 100 mL SF medium and
p63 in Pancreatic Cancer
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26815placed onto the upper compartment of Transwell chambers (8 mm
pore size, Corning Incorporated, Corning, NY). For invasion
assays, cells were suspended in 500 mL SF medium and placed
onto upper compartment of Matrigel-coated Transwell chambers
(8 mm pore size, BioCoat Matrigel Invasion Chambers; BD
Biosciences; Franklin Lakes, NJ). In both Transwell assays, the
lower compartment was filled with 750 mL SF medium in the
absence or presence of 1 nM EGF. After 18–20 h, membranes
were fixed in methanol, stained with toluidine blue (Fisher
Scientific, Pittsburgh, PA) and counted using a light microscope.
Formaldehyde crosslinking, chromatin
immunoprecipitation (ChIP) and PCR amplification
For DNA-histone crosslinking, 2610
6 cells were incubated with
1% formaldehyde in complete medium for 10 minutes. Cells were
washed twice in ice-cold PBS and lysed in SDS Lysis Buffer
(Millipore) complete with protease inhibitor cocktail (Roche).
Protein lysates were sonicated to yield chromatin fragments of
,500 bp as assessed by agarose gel electrophoresis. After pre-
clearing, protein lysates were incubated at 4uC overnight with
2 mg p63a antibodies (H-129, Santa Cruz) or with rabbit IgG as
isotype-specific control antibodies (Santa Cruz). Immunocom-
plexes were washed and DNA was purified using the ChIP Assay
Kit (Millipore) and QiaQuick PCR Purification Kit (Qiagen)
according to the manufacturer’s instructions. PCR conditions
and primers for 14-3-3s consensus binding sites 1 and 2 were
previously reported [17]. The following PCR primers and con-
ditions were used for the EGFR promoter p53 binding site:
forward primer 59 GGCCGCTGGCCTTGGGTC 39; reverse
primer 59 GCCGTGCGCGGTGGTTG 39; 1 cycle of 94uC for
5 min, 43 cycles of 95uC for 30 sec, 55uC for 30 sec, 72uC for
50 sec, followed by 1 cycle of 72uC for 10 min. PCR was
performed using HotStarTaq polymerase Kit (Qiagen), with use of
Q-Solution in the EGFR PCR assay.
Cisplatin-induced apoptosis
Pancreatic cancer cells were incubated for 24 h in complete
medium in the absence or presence of 5 or 10 mg/mL cisplatin for
the initial 2 h, 6 h or the entire 24 h. Both floating and adherent
cells were collected and subjected to immunoblotting.
Results
DNp63a expression in pancreatic cancer cell lines
We found that p63 was differentially expressed in pancreatic
cancer cell lines. p63 protein levels were highest in T3M4 and
BxPC3 cells, intermediate in COLO-357 and below the detec-
tion level in ASPC-1 and PANC-1 cells (Fig. 1A). Since the p63
antibody (clone 4A4) recognized all six known isoforms of p63, we
compared p63 mRNA transcript levels in the above cell lines. All
the cell lines expressed low levels of TAp63 mRNA (Fig. 1B). By
contrast, DNp63 mRNA transcripts were relatively elevated in
BxPC3, COLO-357, and T3M4 cells (Fig. 1B).
To further elucidate whether a particular splicing variant of p63
is expressed in pancreatic cancer cell lines, we employed semi-
quantitative RT-PCR with p63 splicing variant-specific primers
(Table S1). We confirmed that TAp63a mRNA transcripts were
expressed at relatively low and similar levels in all five cell lines. By
contrast, DNp63a mRNA transcripts were only expressed in
BxPC3, COLO-357, and T3M4 cells, whereas DNp63c mRNA
was barely detectable in BxPC3 and T3M4 cells (Fig. 1C).
Although p63a can be detected in a specific PCR assay, isolated
detection of p63b mRNA transcripts is unreliable since its C-
terminus is not unique (Fig. S1). In our experiments, expression of
DNp63b mRNA transcript correlated with DNp63a expression,
probably due to non-specific amplification of DNp63a. Since we
detected p63 protein migration at ,68 kDa, and DNp63b protein
migrates at ,52 kDa [18–20], we concluded that DNp63a was the
predominantly expressed p63 variant in pancreatic cancer cells.
Oncogenic effects of DNp63a in pancreatic cancer cells
To study the biologic effects of DNp63a in PDAC, we
manipulated its expression in PANC-1 and T3M4 cells, which
had low and high endogenous levels of DNp63a, respectively
(Fig. 1). PANC-1 cells were transiently transfected with a DNp63a-
expressing vector (PANC-1DN), a TAp63a-expressing vector
(PANC-1TA), or control plasmid. Lentiviral-mediated shRNA
was used to down-regulate p63 gene isoforms in T3M4 cells. Two
different shRNA sequences, one complementary to a sequence
within a p63 DNA-binding domain (sh DBD) and thus targeting
all isoforms of p63, and another complementary to a sequence
within sterile alpha motif domain (SAM) and thus targeting
TAp63a and DNp63a (sh p63a) were determined to reduce the
DNp63a protein and transcript levels in T3M4 cells (Fig. 2A).
While shRNA targeting trans-activation domain (sh TAp63)
resulted in reduced TAp63 transcript levels, this did not translate
into an appreciable change in the total p63 protein levels (Fig. 2A),
confirming our observation that DNp63a variant predominates in
pancreatic cancer cell lines.
Since anchorage-independent growth is a hallmark of malignant
cells, we studied whether DNp63a has an effect on anchorage-
independent growth and cell proliferation in PDAC. PANC-1DN,
but not PANC-1TA cells exhibited increased colony formation in
soft agar assays and increased cell proliferation in MTT assays
(Fig. 2B). Since T3M4 cells are incapable of forming colonies in
soft agar, proliferation was studied in a clonogenic assay. As
compared with control cells, proliferation of T3M4 cells was
reduced in response to shRNAs that target the DBD or the a-
specific C-terminus and unchanged in response to sh TAp63
(Fig. 2C). Transient overexpression of mouse DNp63a cDNA,
which carries a silent mutation in the region targeted by the a-
specific shRNA, resulted in a partial rescue of the proliferative
ability of sh p63a T3M4 cells, as compared with cells transfected
with control vector (Fig. 2C).
DNp63a is known to regulate the adhesion program in
mammary epithelial cells and keratinocytes [15]. Given the
importance of cell adhesion in tumor invasion and progression,
we studied the effects of DNp63a on the motility and invasive
capabilities of the pancreatic cancer cells. In wound-healing assays,
PANC-1DN cells demonstrated enhanced motility in SF condi-
tions, while overexpression of TAp63a had no effect (Fig. 2D).
Since activation of the EGFR pathway is associated with increased
tumor aggressiveness and decreased survival in PDAC [21], we
sought to determine the effect of EGF on motility. EGF
stimulation enhanced migration in PANC-1DN and control cells
(Fig. 2D). Similarly, T3M4 cells expressing sh p63a, but not sh
TAp63, exhibited reduced motility both at baseline and in
presence of EGF (Fig. 2E). Transient overexpression of mouse
DNp63a in T3M4 cells expressing sh p63a resulted in a partial
rescue of the motility phenotype (Fig. 2F). Manipulation of
DNp63a expression levels had no effect on the invasion of
pancreatic cancer cells in Matrigel chambers in SF conditions
(Fig. 2G, H). However, stimulation with EGF led to a dramatic
increase in the invasive capability of PANC1-DN cells (Fig. 2G).
Consistent with the above findings, shRNA-mediated suppression
of DNp63a, but not TAp63, significantly reduced the ability of
T3M4 cells to invade through Matrigel in response to EGF
stimulation (Fig. 2H).
p63 in Pancreatic Cancer
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colony-forming, proliferative and invasive capacity of the pancre-
atic cancer cells.
DNp63a upregulates EGFR and sensitizes pancreatic
cancer cells to the effects of EGF
Compared with the normal pancreas, EGFR protein and
mRNA are expressed at high levels in pancreatic cancer [22].
EGFR mRNA expression predicts decreased survival and poor
response to chemotherapy in patients with PDAC [23]. In our
work, DNp63a dramatically potentiated pancreatic cancer cell
motility and invasive abilities in the presence of EGF. To explain
this phenomenon, we studied the effect of DNp63a on EGFR
levels. We determined that engineered expression of DNp63a in
PANC-1 cells enhanced EGFR expression, while ectopic TAp63a
had no effect (Fig. 3A). Consistent with this observation, we found
that EGFR levels were decreased in T3M4 cells in response to
shRNA-mediated suppression of DNp63a (Fig. 3B), thus docu-
menting a direct correlation between DNp63a and EGFR
expression in pancreatic cancer cell lines. To study the effects of
DNp63a overexpression on EGFR signaling, we assessed activa-
tion of downstream kinases upon EGF stimulation. Treatment of
PANC1-DN cells with EGF resulted in enhanced phosphorylation
of ERK, Akt and JNK (Fig. 3C). In those cells, all three kinases
exhibited increased level of activation at as early as 10 minutes
after cell stimulation, and ERK activity persisted for 60 minutes.
Next, we employed a tyrosine kinase inhibitor to assert that the
effects of DNp63a were mediated through the EGFR pathway.
Erlotinib is a reversible inhibitor of the EGF signaling, which
associates with the ATP-binding site of the receptor. Incubation
of PANC-1 cells with 1 mM erlotinib attenuated the DNp63a-
mediated enhancement of colony formation, motility and invasion
(Fig. S2), thus excluding a possibility of a non-specific effect. By
contrast, p63 protein levels were not affected when cells were
incubated with either EGF or erlotinib (data not shown).
Previous reports suggested that DNp63a is able to regulate cell
adhesion proteins in mammary epithelial cells [15]. Since integrin-
mediated tumor cell interactions with the extracellular matrix play
Figure 1. Expression of 14-3-3s, p63 isoforms and p53 in pancreatic cancer cell lines. A, Protein levels of p63, 14-3-3s, TAp63c and p53 in
pancreatic cancer cell lines. B, mRNA expression of TAp63 and DNp63 isoforms of p63 in pancreatic cancer cell lines. Total RNA isolated from PDAC
cell lines was reverse-transcribed and subjected to real-time PCR with probes specific for DN and TA isoforms of p63. Results were normalized to 18S
levels, and expressed as mean of two independent experiments done in duplicates in which similar results were obtained. C, mRNA expression of p63
splicing variants in pancreatic cancer cell lines. Levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) values.
doi:10.1371/journal.pone.0026815.g001
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investigated whether DNp63a had an effect on integrin expression
in pancreatic cancer cells. Ectopic expression of DNp63a in
PANC-1 cells increased expression of b1-integrin, whereas the
expression of a3- and a5-integrins was unchanged (Fig. 3A).
Conversely, shRNA-mediated suppression of DNp63a led to a
decrease in b1-integrin in T3M4 cells (Fig. 3B).
Thus, DNp63a contributes to the oncogenic potential of
pancreatic cancer cells, at least in part, through upregulation of
EGFR and b1-integrin.
DNp63a contributes to chemotherapy resistance in
pancreatic cancer cells
Since PDAC is notoriously resistant to chemotherapy agents, we
studied the role of DNp63a in chemotherapy resistance. It has
been previously shown that cisplatin induces degradation of
DNp63a via stimulation of IkB kinase [24]. Consistent with those
data, incubation of pancreatic cancer cell lines with 10 mg/ml of
cisplatin resulted in degradation of endogenous DNp63a. This
effect of cisplatin was evident after 6 hours of incubation and was
accompanied by increased apoptosis in all tested cell lines (Fig. 4A).
We then investigated whether ectopic expression of DNp63a
would contribute to resistance to cisplatin-induced apoptosis in
PDAC. PANC-1 cells were incubated for 24 hours in complete
medium supplemented with 5 mg/mL cisplatin for 2, 6, or 24
hours. PANC-1DN cells exhibited a mild attenuation of apoptosis
compared with control cells, as manifested by decreased PARP and
caspase cleavage (Fig. 4B). This decrease in cisplatin-induced
apoptosiscorrelatedwithanincrease inviabilityofPANC-1DNcells
as determined in an MTT assay, while PANC-1TA cells exhibited a
slightly reduced survival (Fig. 4C). By contrast, T3M4 cells
expressing sh p63a were sensitized to cisplatin-induced apoptosis,
as demonstrated by an increased cleavage of PARP and caspase
(Fig. 4D). Thus, DNp63a attenuates the sensitivity of pancreatic
cancer cells to cisplatin.
DNp63a upregulates 14-3-3s in pancreatic cancer cell
lines
Next we studied the mechanisms of DNp63a-mediated che-
moresistance in PDAC. We have previously shown that 14-3-3s
dramatically enhances resistance to cisplatin-induced apoptosis in
pancreatic cancer cell lines [11]. Westfall et al. demonstrated that
DNp63a acts as a transcriptional repressor of the 14-3-3s promoter
in human epidermal keratinocytes [25]. By contrast, we observed
that expression of DNp63a correlated with 14-3-3s protein
expression in pancreatic cancer cells (Fig. 1A). Additionally,
silencing DNp63a was accompanied by reduction in 14-3-3s
protein level in T3M4 cells (Fig. 2A). 14-3-3s is a p53
transcriptional target, yet BxPC3, PANC-1 and T3M4 cells are
known to carry mutant p53 whose transcriptional activity is
defective [26], while COLO-357 cells express low p53 protein
levels (Fig. 1A). Hence, 14-3-3s expression is unlikely to be
dependent on p53 in PDAC.
To determine if DNp63a modulates 14-3-3s expression in
pancreatic cancer cells, we introduced DNp63a cDNA via
adenoviral infection in ASPC-1 and PANC-1 cells, which express
low levels of 14-3-3s and DNp63a. We observed an increase in
14-3-3s protein levels in the DNp63a overexpressing cells
compared to the control-infected cells (Fig. 5A). This DNp63a-
mediated increase in 14-3-3s was not associated with alterations
of protein levels of the other 14-3-3 isoforms (Fig. 5A). By contrast,
manipulation of 14-3-3s levels in PANC-1 and T3M4 cells did not
have an effect on DNp63a (Fig. 5B and 5C).
Next, we determined whether upregulation of 14-3-3s by
DNp63a is of biological significance in PDAC. Using a lentiviral
based approach we silenced endogenous 14-3-3s in PANC-1 cells.
In such cells, enforced expression of DNp63a failed to upregulate
14-3-3s (data not shown). Consistent with our previous observa-
tions, loss of 14-3-3s did not affect migration abilities of PANC-1
cells in the presence of EGF [[11], Fig. 5E]. Similarly, DNp63a-
mediated enhancement in cell motility was not influenced by the
lack of 14-3-3s (Fig. 5E). By contrast, 14-3-3s was required for
DNp63a-mediated anchorage-independent growth and invasion
in presence of EGF (Fig. 5D and 5F). Thus, DNp63a upregulates
14-3-3s in pancreatic cancer cells which then contributes to
DNp63a-mediated anchorage-independent growth and invasion.
DNp63a is a transcriptional activator of EGFR and
14-3-3s in pancreatic cancer
DNp63a is a regulator of the transcriptional activities of the p53
family member proteins. As such, DNp63a may inhibit transcrip-
tion via its dominant negative effect on p53 and TAp63c [27]. In
addition, the DN variant is able to trans-activate p53 target genes
via binding to p53 responsive elements within the corresponding
gene promoters. While TAp63c is a potent gene trans-activator
due to the absence of an auto-inhibitory domain [27], recent work
demonstrated that it has a very low ability to bind the p53
responsive element within the EGFR promoter, and in fact
represses promoter activity [28]. Since pancreatic cancer cell lines
expressed very low levels of the TAp63 isoform, and since we
found no correlation between DNp63a and TAp63c expression in
those cell lines (Fig. 1A), the dominant negative effect of DNp63a
Figure 2. Effect of DNp63a on anchorage-independent growth, motility, and invasion in pancreatic cancer cells. A, T3M4 cells were
infected with GFP-expressing virus, or p63-specific shRNA complementary to DBD, TA and a-specific domains of p63. Whole-cell protein lysates were
subjected to immunoblotting (top panel). Total RNA was isolated, reverse-transcribed and subjected to real-time PCR with probes specific for DN and
TA isoforms of p63. Results were normalized to 18S levels (bottom panel). Knockdown of p63 isoforms was routinely monitored during the
subsequent experiments. B, DNp63a stimulates anchorage-independent growth of PANC-1 cells in soft agar assay (left and bottom panels) and cell
proliferation in MTT assay (right panel). PANC-1 cells were transiently transfected with DNp63a-expressing vector, TAp63a or control vector. Cell were
plated in soft agar at a density of 1500/well of a 12-well plate, four wells per sample. Colonies were counted after 14 days of incubation. For MTT
assay cells were plated in 96-well plates, six wells per sample. MTT was added after incubation for 48 h. Data are the mean 6 SE of four independent
experiments. *, p,0.001 compared with control. C, Downregulation of DNp63a slows proliferation of T3M4 cells in a clonogenic assay. Reconstitution
of DNp63a partially restores the proliferative ability. Cells were plated on 6 well plates at a density of 500 cells/well. 14 days later, plates were fixed in
3:1 methanol:glacial acetic acid and stained with 2% crystal violet. Data are the mean 6 SE of three independent experiments done in triplicates.
*, p,0.01 compared with control (sh ctrl). D–F, Effect of p63 on cell motility measured in wound-healing assays in PANC-1 (D) and T3M4 cells (E, F).
Cells were incubated in serum-free (SF) conditions in the absence or presence of 1 nM EGF for 18 h after making a scratch. Quantitative analysis of
the images was performed. Ectopic expression of mouse DNp63a in sh p63a T3M4 cells resulted in a partial restoration of cell motility (F);
corresponding DNp63a protein levels shown below. Data are the m 6 SE of at least three independent experiments. Representative pictures shown
(magnification640). *, p,0.001 compared with control (sh ctrl). G and H, Effect of DNp63a on the invasion in Matrigel chambers. PANC-1 (G) or T3M4
(H) cells were plated in Matrigel chambers (5610
4/ml) and incubated in absence (SF) or presence of 1 nM EGF for 18 hours. Effect was normalized to
invasion of control in SF conditions. *, p,0.001 compared with control (sh ctrl).
doi:10.1371/journal.pone.0026815.g002
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expression. Both EGFR and 14-3-3s promoters contain well-
conserved p53 binding sites, suggesting they are transcriptional
targets of DNp63a in PDAC. The 14-3-3s promoter is known to
be unmethylated in pancreatic cancer cell lines [29].
DNp63a requires an intact DNA-binding domain for its
transcriptional activity [18]. We generated a mutant vector
where we introduced a missense mutation into human DNp63a
cDNA sequence resulting in a single amino acid substitution at
position 202 (DNp63a
DBDmut; Fig.S3). Enforced expression of
DNp63a
DBDmut in PANC-1 cells resulted in a detectable DNp63a
protein, but failed to upregulate 14-3-3s (Fig. 6A) indicating that
the ability of DNp63a to upregulate 14-3-3s is dependent upon its
ability to bind to DNA.
We tested if DNp63a was able to activate EGFR promoter in an
in vitro luciferase assay. The details of the p53 binding sites within
Figure 3. DNp63a upregulates EGFR expression and signaling in pancreatic cancer cells. A, Ectopic expression of DNp63a results in
increased expression of EGFR and b1-integrin in PANC-1 cells. After cells were incubated for 48 hours, total protein lysates were subjected to
immunoblotting. A representative image of three independent experiments is shown. B, Downregulation of DNp63a in T3M4 cells results in
decreased expression of EGFR and b1-integrin. A representative image of three independent experiments is shown. C, PANC-1DN and PANC-1 control
cells were stimulated with EGF during indicated time periods. Protein lysates were subjected to immunoblotting. A representative image of three
independent experiments is shown.
doi:10.1371/journal.pone.0026815.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26815Figure 4. DNp63a contributes to chemoresistance in pancreatic cancer cells. A, Effect of cisplatin on DNp63a in PDAC. Cells were incubated
with 10 mg/mL cisplatin for the initial 6 or full 24 hours. Apoptosis was assessed by monitoring PARP cleavage. B–D, Effect of DNp63a on cisplatin-
induced apoptosis in PANC-1 (B, C) and T3M4 cells (D). Cells were incubated with 5 mg/mL of cisplatin during indicated time periods. Cells were
pelleted after 24 h of incubation, proteins isolated and run on SDS-PAGE gel. Apoptosis was assessed by monitoring PARP and caspase-3 cleavage. A
representative image of at least three independent experiments is shown. PANC-1 cells were incubated with 10 mg/mL of cisplatin for the first
12 hours or full 48 hours. MTT assay was done as described in materials and methods. Data are the mean 6 SE of three independent experiments.
doi:10.1371/journal.pone.0026815.g004
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published previously [10]. Ectopic expression of DNp63a resulted
in a dramatic increase of the activity of EGFR reporter plasmid in
PANC-1 cells (Fig. 6B). The effect of DNp63a significantly
exceeded that of wild-type p53 and TAp63a. Next, we introduced
a single nucleotide mutation within the p53 BS 1 of the EGFR
promoter. Specifically, cytosine was replaced with thymidine at
position 2241 (EGFR
C(2241)T). As a further confirmation of our
findings, co-transfection of a mutant EGFR reporter plasmid with
wild-type DNp63a, or wild-type EGFR reporter plasmid and
mutant DNp63a
DBDmut resulted in attenuated luciferase activity
(Fig. 6B). Consistent with this observation, ectopic expression of
Figure 5. DNp63a upregulates 14-3-3s in pancreatic cancer cells. A, ASPC-1 and PANC-1 cells were infected with adenovirus containing either
empty vector or full length DNp63a, and whole cell protein lysate was prepared 48 hours after infection and probed with anti-DNp63a and 14-3-3s
and other 14-3-3 isoforms. B, Overexpression of 14-3-3s had no effect on DNp63a levels. PANC-1 cells were transfected with an empty vector (Sham)
or with the full-length human 14-3-3s cDNA that was tagged with HA. C, Silencing 14-3-3s does not affect DNp63a. T3M4 cells were infected with
lentivirus containing control or 14-3-3s specific shRNAs (sh 14-3-3s 1 and 2), whole cell lysates were prepared 72 hrs post infection and probed for
DNp63a and 14-3-3s. D–F. 14-3-3s is required for the oncogenic effects of DNp63a in PDAC. PANC-1 cells were infected with control sh RNA or sh 14-
3-3s 2. Subsequent to that, cells were transiently transfected with DNp63a-expressing vector or vector control. D, Anchorage-independent growth.
Cells were incubated in soft agar as described in the methods. Data are the mean 6 SE of three independent experiments. E, Cells (5610
4/well) were
subjected to a migration assay in Transwell chambers in the presence of EGF (1 nmol/L) for 18 hours in duplicates. Data are the mean 6 SE of three
independent experiments. F, Cells were subjected to invasion in Matrigel chambers in the presence of EGF (1 nmol/L) for 20 h in duplicates. Data are
the mean 6 SE of three independent experiments.
doi:10.1371/journal.pone.0026815.g005
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26815Figure 6. DNp63a is a transcriptional activator of EGFR and 14-3-3s in pancreatic cancer cells. A, DNp63a
DBDmut does not upregulate 14-
3-3s. B and C, DNp63a upregulates EGFR and 14-3-3s promoter in a luciferase assay. PANC-1 cells were transfected with wildtype EGFR, mutant EGFR
or 14-3-3s promoter luciferase construct as indicated, along with pCMVb plasmid, with or without wildtype p53, DNp63a, DNp63a
DBDmut, or TAp63a.
At 48–72 h after transfection, the luciferase activity was determined. The transfection efficiency was standardized against b-galactosidase activity.
Results are indicative of four independent experiments. *, p,0.0001. D, p63 binds EGFR and 14-3-3s promoters in T3M4 cells. Binding is decreased
upon serum-starvation. T3M4 cells were grown in medium containing 10% FBS (rapidly growing cells) or in serum-free medium (predominantly
resting cells). Cells were pelleted and ChIP was performed as described in materials and methods. Uncrosslinked protein lysate, protein lysate
immunoprecipitated with an irrelevant antibody, and a protein lysate immunoprecipitated with p63 antibody, but where irrelevant DNA sequences
located ,3000 bp downstream of the 14-3-3s or EGFR promoter regions were amplified served as negative controls (the latter not shown).
doi:10.1371/journal.pone.0026815.g006
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plasmid activity in PANC-1 cells, which was attenuated when a
DNp63a
DBDmut expression vector was co-transfected in place of
wild type DNp63a (Fig. 6C).
Next, we tested whether DNp63a is capable of binding EGFR
and 14-3-3s promoters at their corresponding p53 binding sites.
Our ChIP experiments revealed that DNp63a exhibited significant
binding to p53 binding sites in the endogenous EGFR and 14-3-
3s promoters in T3M4 cells (Fig. 6D). Chromatin binding
depended on the growth phase of T3M4 cells as serum starva-
tion resulted in a significant decrease in promoter occupancy
by DNp63a (Fig. 6D), while DNp63a protein expression was
unchanged (data not shown).
We next sought to determine whether the ability of DNp63a to
trans-activate EGFR and 14-3-3s promoters was unique to
pancreatic cancer. We studied HEK293 cells, a transformed non-
malignant cell line, and H1299 cells, a non-small cell lung cancer
cell line [30]. Similar to our pancreatic cancer cells, H1299 cells
carry a mutant p53. While DNp63a is known to be expressed in
non-small cell lung cancer [31], H1299 cells predominantly
express the TAp63 variant [30].
Both HEK293 and H1299 cells expressed lower levels of p63
and 14-3-3s compared to T3M4 pancreatic cancer cells (Fig. 7A).
Engineered expression of DNp63a in these cells did not lead to an
increase in either EGFR or 14-3-3s protein levels (Fig. 7A).
Similarly, DNp63a did not activate the EGFR promoter in either
cell line in an in vitro luciferase reporter assay (Fig. 7B, left panels).
By contrast, DNp63a transactivated the 14-3-3s promoter in
H1299 cells, albeit to a lesser degree than in pancreatic cancer
cells (Fig. 7B, top right panel). In HEK293 cells, DNp63a
repressed the 14-3-3s promoter, similar to what was previously
reported in human keratinocytes [25], whereas in H1299 cells
enforced expression of DNp63a led to an increase in 14-3-3s
mRNA transcript levels (Fig. 7C).
DNp63 has been shown to enhance proliferative capacity in
normal and malignant cells of epithelial origin [32–34]. While
DNp63a stimulated anchorage-independent growth, invasion and
migration of pancreatic cancer cells and sensitized them to EGF,
such effects were not observed in H1299 cells (Fig. 7D).
Collectively, these data indicate that DNp63a binds and trans-
activates the EGFR and 14-3-3s promoters in pancreatic cancer
cells and that these actions of DNp63a do not necessarily occur in
other cell types.
Discussion
Genetic defects which result in inactivation of tumor suppres-
sion genes and accumulation of oncogenic alleles promote
development and progression of PDAC. p53 is a prototypic tumor
suppressor that is vital in cell growth control. However, normal
p53 function is commonly lost in PDAC. p53 homolog p63
possesses an N-terminal trans-activation domain (TA), a DNA-
binding domain (DBD) and a C-terminal oligomerization domain
(OD). Studies in knockout mice demonstrated that despite
structural similarity with p53, p63 has distinct functional pro-
perties [35]. Moreover, variability of expression of six known p63
isoforms among normal and malignant tissues suggests that the
functional role of p63 is dependent on the cellular context. TAp63
isoforms may carry an anti-oncogenic potential as they mediate
Ras-induced cellular senescence, antagonize tumorigenesis in vivo
and suppress development of metastases through regulation of
microRNA network [36,37]. The role of DNp63 in cancer is less
clear. Recent studies have indicated that DNp63a is necessary and
sufficient to by-pass oncogene-induced senescence suggesting that
it plays a critical role in the very early steps of cancer initiation
[38]. Overexpression of DNp63 is found in cancers of epithelial
origin (lung, head and neck), where it promotes tumor survival [7].
DNp63 has been shown to enhance the proliferative capacity of
both epithelial stem cells and cancer cells, and loss of p63 reduced
the proliferative rate of MCF-7 breast cancer cells [32,33].
However, the role of p63 in PDAC is not known. Here we report
that DNp63a is the predominantly expressed p63 isoform in
pancreatic cancer cell lines. We demonstrate that ectopic
expression of DNp63a in PANC-1 cells, which have low p63
mRNA transcript and protein levels, resulted in enhancement of
anchorage-independent growth, cell motility and invasion. Con-
versely, shRNA-mediated suppression of DNp63a in T3M4 cells
resulted in the opposite effect, i.e. decreased proliferation, pro-
migratory and pro-invasive responses. In earlier reports, down-
regulation of endogenous p63 led to enhanced apoptosis in head
and neck squamous cell cancer cell lines irrespective of the p53
gene status [7]. By contrast, exogenous DNp63a induced cell cycle
arrest and apoptosis in p53-null non-small cell lung cancer cells
[39]. In our studies, neither engineered expression of DNp63a, nor
downregulation of endogenous DNp63a induced apoptosis in p53-
mutant pancreatic cancer cells (data not shown). While migration
and invasion are both paramount to embryonic development and
wound healing in normal tissues, in cancer those processes are
involved in local tumor invasion and metastasis. Hence, these data
underscore the importance of DNp63a in tumor progression in
PDAC.
Tyrosine kinase and serine/threonine kinase pathways regulate
multiple cellular processes and are major effectors in PDAC
development [40]. EGFR is a 170 kDa transmembrane glycopro-
tein of the ErbB family of tyrosine kinase growth factor receptors.
EGFR activates Ras/Raf/MAPK-ERK and PI-3 kinase/Akt
pathways leading to increased cell proliferation, reduced apoptosis,
increased angiogenesis, enhanced motility, invasion and metas-
tasis [41]. EGFR signaling blockade via a dominant negative
mechanism leads to reduction in mitogenic activity in pancreatic
cancer cells through decreased activation of MAPK pathway [42].
In our experiments, DNp63a enhanced EGF-mediated motogenic
effects and potentiated EGFR signaling as evidenced by enhanced
phosphorylation of ERK and Akt and increased activation of JNK
in PANC-1DN cells. We and others previously reported that EGF
is capable of promoting cancer cell growth through JNK activation
[42,43]. Suppression of DNp63a in T3M4 cells resulted in a
remarkable attenuation of EGF-mediated invasion. Collectively,
these observations suggest that PDAC requires DNp63a to fulfill
its pro-invasive potential in response to EGF stimulation.
Clinical trials of EGFR-targeting agents reported modest effects
on patient survival in PDAC [44,45]. The therapeutic efficacy of
these agents could be improved if regulation of EGFR signaling
was better understood. Here we provide evidence of a functional
interplay between DNp63a and EGFR in pancreatic cancer.
Ectopic expression of DNp63a, but not TAp63a, resulted in
increased EGFR protein levels in PANC-1 cells. Conversely,
downregulation of DNp63a in T3M4 cells led to a decreased
expression of EGFR. It was initially felt that whereas TAp63 is a
strong gene trans-activator, DNp63 functions as a dominant
negative isoform [27]. However, recent findings point out that
DNp63 is able to trans-activate p53 target genes as well as distinct
targets [46,47]. TAp63c has been reported to repress EGFR
promoter activity in H1299 lung cancer cells [28]. However, we
determined that DNp63a is a transcriptional activator of EGFR in
pancreatic cancer cells, but not in HEK293 or H1299 cells.
Moreover, compared to p53, DNp63a was a strong trans-activator
of EGFR in a functional reporter assay, and ChIP experiments
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PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e26815Figure 7. A distinct role of DNp63a in HEK293 and H1299 cells. A, DNp63a does not affect EGFR or 14-3-3s protein levels in HEK293 or H1299
cells. Representative blot of three independent experiments is shown. B, DNp63a fails to upregulate EGFR promoter but modulates 14-3-3s promoter
in a luciferase reporter assay. Cells were transfected with wildtype EGFR or 14-3-3s promoter luciferase construct as indicated, along with pCMVb
plasmid, with or without wildtype p53, DNp63a, DNp63a
DBDmut, or TAp63a. At 48–72 h after transfection, the luciferase activity was determined. The
transfection efficiency was standardized against b-galactosidase activity. Results are indicative of three independent experiments performed in
duplicates. C, DNp63a increases 14-3-3s mRNA transcript levels in H1299 cells. H1299 cells were transfected with DNp63a, DNp63a
DBDmut or vector
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binding site. By contrast, TAp63a was a weak transcriptional
activator of EGFR in a functional reporter assay. However,
downregulation of TAp63 isoforms also decreased EGFR
expression in T3M4 cells, suggesting that in those cells TAp63
isoforms could still be contributing to EGFR expression.
PDAC is notoriously resistant to conventional chemotherapy
agents. This is partly explained by frequent inactivation of p53 in
pancreatic tumors and thus unresponsiveness to genotoxic
stress. Here we demonstrate that DNp63a further contributes to
chemotherapy resistance in PDAC. While overexpression of
DNp63a in PANC-1 cells resulted in a marginal increase in
apoptotic death upon exposure to cisplatin, its downregulation in
T3M4 cells led to a markedly increased sensitivity of those cells
to cisplatin-induced apoptosis. Similar to our observations in
pancreatic cancer cells, cisplatin induces proteosomal degradation
of DNp63a in other cell types [24]. Additional mechanisms that
contribute to cisplatin resistance in pancreatic cancer include
overexpression of cyclin D1 [48] and multidrug resistance-
associated proteins [49]. Moreover, DNp63a itself may promote
chemoresistance through several mechanisms. For example, it can
have a dominant negative effect on the proapoptotic partners
within the p53 family, as suggested by earlier experiments
performed in head and neck and breast cancer [6]. Although
DNp63a contributed to chemoresistance through regulation of
Akt1 expression in ovarian and head and neck cancer [50], we did
not observe such effect in pancreatic cancer cells (Fig. 3A).
However, we highlight a new potential mechanism of DNp63a-
mediated chemoresistance in PDAC. In our earlier experiments,
14-3-3s dramatically increased chemoresistance and enhanced
the pro-invasive potential of pancreatic cancer cells [11]. Here we
demonstrate that expression of 14-3-3s protein correlates with
DNp63a levels in those cells. While others have identified 14-3-3s
as a DNp63 repression target in human embryonic keratinocytes
[25], we established that DNp63a activates the 14-3-3s promoter
and upregulates 14-3-3s protein expression in pancreatic cancer
cells (and in H1299 lung cancer cells), thus decreasing sensitivity of
pancreatic cancer cells to cisplatin-induced apoptosis. This
discrepancy provides additional evidence that DNp63a actions
are tissue-specific, and its function in cancer is distinct from its role
in embryonic cells. We also found that 14-3-3s promoter binding
by DNp63 was more pronounced in rapidly cycling as compared
with resting T3M4 cells. This suggests that at least some DNp63a
target sites may be poorly accessible in quiescent cells and
require chromatin remodeling to occur prior to binding, further
implicating cellular context in modulation of p63 function.
In our immunoprecipitation experiments we found no interac-
tion between p63 and 14-3-3s proteins (data not shown), however
14-3-3s contributed to the mitogenic and motogenic effects of
DNp63a in PDAC. Lentiviral knockdown of 14-3-3s resulted in a
dramatic attenuation of the effects of DNp63a on anchorage-
independent growth and EGF-stimulated invasion of PANC-1
cells. Silencing of 14-3-3s had no consequences on the effects of
DNp63a on cell motility, leading to the conclusion that DNp63a
affects migration through potentiation of the other signaling
pathways, i.e. EGFR and integrins.
p63 controls the adhesion program in MCF-10A mammary
epithelial tissues through transcriptional regulation of integrins
[15]. A number of integrin subunits have been shown to be
upregulated in PDAC [51]. We demonstrate that DNp63amodulates
expression of b1-integrins, which are involved in regulation of cell
adhesion and migration of tumor on stroma proteins, thus further
implicating DNp63a in pancreatic carcinogenesis. Importantly,
integrin and EGFR pathways are closely intertwined and orchestrate
cancer growth and invasion. Integrin-mediated adhesion of cells to
extracellular matrix induces EGFR activation in a ligand-indepen-
dent manner, while EGFR regulates integrin signaling and is
necessary for adhesion-induced activation of ERK and other
signaling molecules [52]. Cross-talk between integrins and EGFR
family members affects multiple aspects of tumor progression,
including proliferation, migration and invasion [53]. For example,
blockade of integrin avb5 reverses the EGF-stimulated invasion and
metastasis in pancreatic cancer cells [54]. On the other hand,
overexpression of b1-integrin has been shown to correlate with
acquired resistance to EGFR inhibitors in lung cancer [55]. The
unique ability of DNp63a to regulate both EGFR and b1-integrin in
PDAC renders it a particularly promising therapeutic target.
In conclusion, DNp63a is the predominantly expressed p63
variant in PDAC cell lines with oncogenic properties. In PANC-1
and T3M4 cells DNp63a enhanced anchorage independent
growth, cell proliferation, and basal and EGF-stimulated motility
and invasion and conferred chemoresistance. The oncogenic
effects of DNp63a were mediated via transcriptional activation of
EGFR and 14-3-3s. Our observations indicate that targeting
DNp63a and 14-3-3s may present a strategy to potentiate the
efficacy of EGFR-targeting therapies in PDAC.
Supporting Information
Table S1 p63 primer sequence and expected size of
PCR products.
(DOC)
Figure S1 Genomic structure of human p63 and location
of primers and sh RNA complementary sites. Genomic
structure of human p63 on chromosome 3 and schematic
representation of the six variants of p63. TA – trans-activation
domain, DBD – DNA-binding domain, OD – oligomerization
domain, SAM – sterile alpha motif, TID – transactivational
inhibitory domain.
(TIF)
Figure S2 Erlotinib attenuates DNp63a-mediated en-
hancement of migration, invasion and anchorage-inde-
pendent growth in PANC-1 cells. A, Erlotinib attenuates
DNp63a-mediated anchorage-independent growth of PANC-1
cells in soft agar assay. Soft agar assay was performed as described
previously in presence of 1 mM erlotinib or vehicle control. B,
PANC-1 cells (5610
4/well) were subjected to a migration assay in
Transwell chambers in presence of EGF (1 nmol/L) as described
above, with or without 1 mM erlotinib. C, PANC-1 cells (1610
4/
well) were subjected to invasion assay in Matrigel chambers in
presence of EGF (1 nmol/L) as described above, with or without
1 mM erlotinib. *, p,0.05 compared with control.
(TIF)
Figure S3 DNp63a
DBDmut cDNA-expressing vector. Par-
tial sequence of the DNp63a cDNA shown (nucleotides
control. At 36 hours total RNA was isolated, reverse-transcribed and subjected to real-time PCR with probe specific for 14-3-3s. Results were
normalized to 18S levels. Data are the mean of two independent experiments done in duplicates in which similar results were obtained. D, DNp63a
does not enhance anchorage-independent growth, migration or invasion in H1299 cells. H1299 cells were transfected with DNp63a or vector control.
Soft agar, transwell migration and invasion assays were performed as described above. *, p,0.05 compared with control.
doi:10.1371/journal.pone.0026815.g007
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capital.
(TIF)
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